NasdaqGM:GPCRPharmaceuticals
Why Structure Therapeutics (GPCR) Is Up 21.7% After Promising Phase 2 Oral Obesity Drug Data
Structure Therapeutics recently reported encouraging Phase 2 trial results for its oral obesity drug candidate aleniglipron, coinciding with renewed attention on GLP-1 weight-loss treatments following US FDA approval of a competing therapy from Eli Lilly.
The combination of promising oral obesity data and rising institutional interest highlights how Structure Therapeutics has become more central to the fast-evolving obesity treatment landscape.
We’ll now examine how the promising Phase 2...